Business Overview: Septerna, Inc. (NASDAQ: SEPN)

---

Executive Summary

Septerna, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, built around a proprietary drug-discovery platform for one of the hardest-to-drug target classes in pharmacology: G protein-coupled receptors (GPCRs). Its Native Complex Platform® reconstitutes full-length GPCRs outside of living cells in their native, functional conformation, allowing structure-based design of oral small-molecule drugs against receptors that have historically only been reachable with injectable biologics or peptides.

Septerna went public on Nasdaq in 2024 and has since built a pipeline of internally discovered, wholly owned clinical programs — most notably an oral therapy for hypoparathyroidism and an oral candidate for chronic spontaneous urticaria (CSU) — while also monetizing the platform through partnership. In July 2025, Novo Nordisk paid Septerna a $195.0 million non-refundable upfront payment to access the platform for metabolic-disease GPCR targets, with Septerna eligible for up to approximately $498.0 million in additional milestones plus tiered royalties, and Novo funding 100% of the related R&D. That single transaction is why Septerna, despite having no approved products, is a substantively funded, revenue-generating operating company rather than a speculative pre-revenue shell.

---

1. Core Business Model & How They Work

Septerna operates the classic clinical-stage biotech model, but with a platform-licensing layer that differentiates it from a typical single-asset biotech:

[ Native Complex Platform® (full-length GPCR reconstitution) ] ➡️ [ Structure-Based Drug Design ] ➡️ [ Preclinical / IND-Enabling Studies ] ➡️ [ Clinical Trials ] ➡️ [ Wholly-Owned Program Commercialization  — OR —  Partnered Program (upfront + milestones + royalties, e.g. Novo Nordisk) ]

Key Operational Drivers

1. Platform-first approach to an historically "undruggable" target class: Roughly a third of all approved drugs act on GPCRs, but most GPCR-targeted medicines today are injectable biologics or peptides because the receptors are difficult to isolate and study outside the cell membrane. Septerna's platform is built specifically to make oral, small-molecule GPCR drugs tractable.
2. Dual monetization — wholly owned pipeline plus partnerships: Septerna retains full ownership of lead programs like its hypoparathyroidism and CSU candidates, while separately licensing platform access to well-funded partners (Novo Nordisk) for other GPCR target areas, generating near-term cash without diluting ownership of its core pipeline.
3. Collaboration economics: the Novo Nordisk deal structure — large upfront payment, 100% R&D cost reimbursement, milestone payments, and royalties (plus an option for profit-and-loss sharing on one candidate instead of milestones/royalties) — is a capital-efficient way for a clinical-stage company to fund platform expansion without taking on debt or heavily diluting equity.
4. Regulatory and clinical execution risk is concentrated in a small number of lead assets, as is typical for any clinical-stage biotech — value today is driven far more by trial readouts than by current revenue.

---

2. Product Portfolio

Septerna is single-segment (platform-based GPCR drug discovery); rather than a product-revenue table, its value drivers are its pipeline programs and platform deal:

---

3. Competitive Landscape

Septerna's 10-K describes competitors only in general terms ("several large pharmaceutical and biotechnology companies" and other GPCR-focused firms), without naming specific rivals in its own competition section, but the broader landscape includes:

• Other structural-biology / GPCR-focused biotechs, pursuing similar goals of making oral small molecules against receptors traditionally targeted by biologics or peptides — the core of Septerna's differentiation claim rests on whether its Native Complex Platform® produces better or faster drug candidates than rival structural approaches.
• Large pharmaceutical and biotechnology companies with their own GPCR drug-discovery efforts and much larger balance sheets, including companies developing injectable or peptide alternatives to the same indications (e.g., Ascendis Pharma, which markets an injectable therapy for hypoparathyroidism that an oral SEP-479 would need to outcompete on convenience and/or efficacy).
• Novo Nordisk itself, as both partner and (in other GPCR areas such as metabolic disease, Novo Nordisk's core franchise) potentially one of the most resourceful possible competitors if the collaboration structure were ever to change.

Because Septerna has no approved products yet, competitive positioning today is mostly about platform credibility and partnership validation rather than market share — the Novo Nordisk deal is itself evidence that a major, well-resourced pharmaceutical company judged the platform credible enough to pay a nine-figure upfront fee for access.

---

4. Strategic Strengths & Risks

Strategic Strengths

• Proprietary platform addressing a large, underexploited target class: GPCRs underlie a large share of approved drugs, but the oral small-molecule GPCR space remains comparatively underdeveloped relative to biologics — Septerna's Native Complex Platform® is purpose-built to compete there.
• Major partner validation and non-dilutive funding: the $195.0 million Novo Nordisk upfront payment, full R&D cost reimbursement, and up to ~$498.0 million in additional milestones materially de-risk Septerna's balance sheet relative to a typical clinical-stage biotech with no partnered revenue.
• Pipeline diversity across multiple indications (hypoparathyroidism, CSU, Graves'/thyroid eye disease, and partnered metabolic targets) reduces single-asset binary risk somewhat, though all programs remain pre-approval.

Strategic Risks

• No approved products and no product revenue: Septerna's revenue today is collaboration-derived, not product-derived; all wholly-owned pipeline value depends on successful, expensive, multi-year clinical trials with normal biotech attrition risk.
• Concentration in early-stage assets: SEP-479 and SEP-631 are the company's most advanced wholly-owned programs; a negative clinical readout on either would be a significant setback to the standalone (non-partnered) part of the business.
• Dependence on a single large partner for near-term cash economics: while the Novo Nordisk deal is a strength today, it also means a meaningful share of Septerna's near-term financial profile is tied to the continuation and performance of one collaboration.
• Platform-novelty risk: because the Native Complex Platform® is a relatively new approach, its long-run track record of converting structural insights into approved, differentiated drugs is still unproven at the regulatory-approval stage.

---

5. Financial Overview

---

6. Summary Conclusion

Septerna is a platform biotechnology company betting that GPCRs — a target class long reached mainly with biologics and peptides — can be systematically drugged with oral small molecules using its Native Complex Platform®. The Novo Nordisk collaboration is the clearest near-term validation of that thesis: a top-five global pharmaceutical company paid $195.0 million upfront, agreed to fund 100% of related R&D, and committed to pay up to roughly $498.0 million more in milestones for access to the platform in metabolic disease. The company's own wholly-owned clinical assets (led by an oral hypoparathyroidism candidate and an oral CSU candidate) represent the larger long-term value opportunity but also carry standard, binary clinical-stage biotech risk. Septerna's biggest forward risk is the same as any clinical-stage biotech's: whether its pipeline — and the platform behind it — can actually deliver approved, differentiated drugs, rather than just promising structural biology.